Clinical trials
Observational Coronary Stenosis trials with unknown status
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
24 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 1 |
| 2006 | 1 |
| 2007 | 1 |
| 2009 | 2 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 2 |
| 2013 | 2 |
| 2016 | 2 |
| 2017 | 2 |
| 2019 | 2 |
| 2020 | 1 |
| 2021 | 2 |
| 2023 | 3 |
| 2024 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 24 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Seoul National University Hospital | 2 |
| A.O.U. Città della Salute e della Scienza | 1 |
| China National Center for Cardiovascular Diseases | 1 |
| Chinese Academy of Medical Sciences, Fuwai Hospital | 1 |
| European Cardiovascular Research Center | 1 |
| Fudan University | 1 |
| Guiyang No.4 People's Hospital | 1 |
| Hanyang University Seoul Hospital | 1 |
| Heart Center Leipzig - University Hospital | 1 |
| Hillel Yaffe Medical Center | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Coronary Stenosis | 24 |
| Coronary Artery Disease | 10 |
| Myocardial Ischemia | 6 |
| Cardiovascular Diseases | 4 |
| Coronary Disease | 3 |
| Heart Diseases | 2 |
| Angina Pectoris | 1 |
| Anxiety Disorders | 1 |
| Arterial Occlusive Diseases | 1 |
| Arteriosclerosis | 1 |
Trials
Showing 1 to 24 of 24. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.